Patents by Inventor Gary Probst

Gary Probst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes
    Publication number: 20220062233
    Abstract: Aspects of the present disclosure include methods of reducing the deleterious impact of a target gene in a cell, such as the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a tetrahydrocarbazole compound. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.
    Type: Application
    Filed: December 12, 2019
    Publication date: March 3, 2022
    Inventors: Thomas W. SUN, Gary PROBST, Jason BAIK
  • Substituted cinnolines as inhibitors of LRRK2 kinase activity
    Patent number: 9884828
    Abstract: The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: February 6, 2018
    Assignee: Imago Pharmaceuticals, Inc.
    Inventors: Danielle L. Aubele, Albert W. Garofalo, Simeon Bowers, Anh P. Truong, Xiaocong Michael Ye, Maurizio Franzini, Marc Adler, R. Jeffrey Neitz, Gary Probst
  • INHIBITORS OF LRRK2 KINASE ACTIVITY
    Publication number: 20150284337
    Abstract: The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Application
    Filed: May 21, 2012
    Publication date: October 8, 2015
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Danielle L. Aubele, Albert W. Garofalo, Simeon Bowers, Anh P. Truong, Xiaocong Michael Ye, Maurizio Franzini, Marc Adler, R. Jeffrey Nietz, Gary Probst
  • N-sulfonamido polycyclic pyrazolyl compounds
    Patent number: 8283358
    Abstract: The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R25, R50, and R51 are as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: October 9, 2012
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Andrei W. Konradi, Xiaocong Michael Ye, Simeon Bowers, Albert W. Garofalo, Danielle L. Aubele, Darren Dressen, Raymond Ng, Gary Probst, Christopher M. Semko, Minghua Sun, Anh P. Truong, Michael S. Dappen
  • Process for the Production of Fused, Tricyclic Sulfonamides
    Publication number: 20110034691
    Abstract: The present invention provides methods, i.e., scalable or large-scale processes for the production of fused, tricyclic sulfonamido analogs, such as substituted or unsubstituted 5-(aryl-sulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinolines and 5-(heteroaryl-sulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinolines. Exemplary methods of the invention include an intra-molecular cyclization step, in which a carbon-nitrogen bond is formed, and which employs a copper-based catalyst that contains at least one organic ligand, such as DMEDA. The invention further provides compounds, which are useful as intermediates in the methods of the invention.
    Type: Application
    Filed: March 24, 2010
    Publication date: February 10, 2011
    Inventors: Michael S. Dappen, Jacek J. Jagodzinski, Lee H. Latimer, Jing Wu, Jollie Duaine Godfrey, JR., Robert Michael Matunas, Thomas W. Drabb, Gary Probst
  • Substituted hydroxyethylamine aspartyl protease inhibitors
    Patent number: 7858642
    Abstract: The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: December 28, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Varghese John, Michel Maillard, John Tucker, Jose Aquino, Barbara Jagodzinska, Louis Brogley, Jay S. Tung, Simeon Bowers, Darren Dressen, Gary Probst, Neerav Shah
  • N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS
    Publication number: 20100081680
    Abstract: The current invention provides compounds having a structure according to Formulae 1, 2, 3, and 4: wherein the A-ring, B-ring, C-ring, m, n, R25, R50, and R51 are as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae 1, 2, 3, and 4, as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae 1, 2, 3, and 4.
    Type: Application
    Filed: September 4, 2009
    Publication date: April 1, 2010
    Inventors: Andrei W. Konradi, Xiaocong Michael Ye, Simeon Bowers, Albert W. Garofalo, Danielle L. Aubele, Darren Dressen, Raymond Ng, Gary Probst, Christopher M. Semko, Minghua Sun, Anh P. Truong, Michael S. Dappen
  • SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS
    Publication number: 20090270367
    Abstract: The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: March 3, 2009
    Publication date: October 29, 2009
    Inventors: Varghese JOHN, Michel MAILLARD, John TUCKER, Jose AQUINO, Barbara JAGODZINSKA, Louis BROGLEY, Jay TUNG, Simeon BOWERS, Darren DRESSEN, Gary PROBST, Neerav SHAH
  • OXIME DERIVATIVE SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS
    Publication number: 20090042961
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: May 8, 2008
    Publication date: February 12, 2009
    Inventors: Varghese John, Michel Maillard, Barbara Jagodzinska, Jose Aquino, Gary Probst, Jay Tung
  • Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
    Patent number: 7385085
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: June 10, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Varghese John, Michel Maillard, Barbara Jagodzinska, Jose Aquino, Gary Probst, Jay Tung
  • Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase
    Publication number: 20080021056
    Abstract: The invention provides compounds of formula I: or pharmaceutically salts thereof where R1, R2, and the A, B, and C-rings are as defined herein. Compounds of formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's disease. The invention also encompasses pharmaceutical compositions comprising compounds or salts of formula I, methods of preparing the desired compounds, and methods of treating cognitive disorders, such as Alzheimer's disease, using the compounds or salts of formula I.
    Type: Application
    Filed: June 1, 2007
    Publication date: January 24, 2008
    Inventors: Andrei Konradi, Gary Probst, Danielle Aubele, Albert Garofalo, Roy Hom, Martin Neitzel, Christopher Semko, Anh Truong
  • FACTOR Xa INHIBITORS
    Publication number: 20070185092
    Abstract: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.
    Type: Application
    Filed: January 5, 2007
    Publication date: August 9, 2007
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Shawn Bauer, Zhaozhong Jia, Yonghong Song, Gary Probst, Yanchen Zhang, Robert Scarborough
  • Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
    Publication number: 20070149584
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: July 11, 2005
    Publication date: June 28, 2007
    Inventors: Varghese John, Michel Maillard, Barbara Jagodzinska, Jose Aquino, Gary Probst, Jay Tung
  • Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
    Publication number: 20070149525
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: October 12, 2006
    Publication date: June 28, 2007
    Inventors: Roy Hom, Gergely Toth, Gary Probst, Simeon Bowers, Anh Truong, Jay Tung
  • Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
    Publication number: 20060135581
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: November 17, 2005
    Publication date: June 22, 2006
    Inventors: Varghese John, Michel Maillard, Barbara Jagodzinska, Jose Aquino, Gary Probst, Jay Tung
  • Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
    Publication number: 20060128715
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: July 11, 2005
    Publication date: June 15, 2006
    Inventors: Jennifer Sealy, Roy Hom, Varghese John, Gary Probst, Jay Tung
  • Factor Xa inhibitors
    Publication number: 20060100193
    Abstract: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.
    Type: Application
    Filed: June 20, 2005
    Publication date: May 11, 2006
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Shawn Bauer, Zhaozhong Jia, Gary Probst, Yanchen Zhang, Robert Scarborough
  • Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
    Publication number: 20060014790
    Abstract: The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: January 21, 2005
    Publication date: January 19, 2006
    Inventors: Varghese John, Roy Hom, Jennifer Sealy, Jose Aquino, Gary Probst, Jay Tung, Lawrence Fang
  • Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
    Publication number: 20050239832
    Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: March 9, 2005
    Publication date: October 27, 2005
    Inventors: Varghese John, Michel Maillard, Lawrence Fang, John Tucker, Louis Brogley, Jose Aquino, Simeon Bowers, Gary Probst, Jay Tung
  • Substituted hydroxyethylamine aspartyl protease inhibitors
    Publication number: 20050239836
    Abstract: The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.
    Type: Application
    Filed: March 9, 2005
    Publication date: October 27, 2005
    Inventors: Varghese John, Michel Maillard, John Tucker, Jose Aquino, Barbara Jagodzinska, Louis Brogley, Jay Tung, Simeon Bowers, Darren Dressen, Gary Probst, Neerav Shah